424 | LONGITUDINAL TARGETED ctDNA ANALYSIS TO ASSESS CD20 and BAFF MUTATIONS IN PATIENTS WITH RELAPSED/REFRACTORY FL OR DLBCL PROGRESSING ON ODRONEXTAMAB IN THE ELM‐2 STUDY

Documenti analoghi

• 425 | BIOMARKER ANALYSES OF THE INFLAMMATORY PROFILE AND MRD IN PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA VERSUS FOLLICULAR LYMPHOMA TREATED WITH ODRONEXTAMAB
  di: E. Bachy, et al.
  Pubblicazione: (2025)
• 421 | ctDNA DYNAMICS OF REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA
  di: R. N. Rys, et al.
  Pubblicazione: (2025)
• 41 | PROSPECTIVE VALIDATION OF END OF TREATMENT ctDNA‐MRD BY PhasED‐Seq IN DLBCL PATIENTS FROM A NATIONAL HOVON TRIAL
  di: M. E. Chamuleau, et al.
  Pubblicazione: (2025)
• 426 | EPCORITAMAB+GEMOX LEADS TO HIGH MRD‐NEGATIVITY RATES IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA: AN UPDATED LONGITUDINAL MRD ANALYSIS
  di: K. Karagoz, et al.
  Pubblicazione: (2025)
• 838 | A PHASE 1 TRIAL OF NX‐2127, A FIRST‐IN‐CLASS BTK DUAL‐TARGETED PROTEIN DEGRADER, IN PATIENTS WITH RELAPSED/REFRACTORY B‐CELL MALIGNANCIES
  di: A. Danilov, et al.
  Pubblicazione: (2025)